REG - Polarean Imaging PLC - Key patent in China secured

Polarean ImagingAnnouncement

30/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250130:nRSd1689Va&default-theme=true

RNS Number : 1689V  Polarean Imaging PLC  30 January 2025

Polarean Imaging plc

("Polarean" or the "Company")

 

Key Patent in China Secured

New patent covers the use of Xenon MRI to non-invasively visualise pulmonary
gas exchange and vascular function

 

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in
advanced Magnetic Resonance Imaging ("MRI") of lung function, announces the
issuance of Chinese patent ZL201980047729.5.

 

The new Chinese patent covers the use of Polarean's Xenon MRI platform to
visualise global and regional pulmonary gas exchange and microvascular blood
flow in real time, helping position the Company for a potential future entry
into the Chinese market and underscoring the Company's commitment to tackling
the global burden of lung disease.

 

China has one of the highest burdens of lung disease globally, driven by
factors such as air pollution, smoking, and an aging population, accounting
for nearly a quarter of all chronic obstructive pulmonary disease (COPD) cases
and 40% of new lung cancer cases globally. Chronic conditions like
interstitial lung disease (ILD) and pulmonary hypertension are major
challenges, particularly when symptoms such as unexplained dyspnea
(breathlessness) cannot be clearly diagnosed using conventional tools. By
illuminating hidden aspects of lung function, Polarean's Xenon MRI platform
offers clinicians valuable new insights into complex lung diseases.

 

Christopher von Jako, Ph.D., CEO of Polarean, commented: "This new patent
represents another step forward in our mission to optimise lung health
globally. China faces an immense burden of respiratory diseases, and the
addition of this patent will enable us, when the time is right, to bring our
innovative, non-invasive Xenon MRI platform to a country that urgently needs
it. With our cutting-edge Xenon MRI platform, we aim to deliver novel
diagnostic tools that can improve outcomes for millions of patients with lung
disease."

 

Chase Hall, M.D., Chief Medical Advisor at Polarean, added: "China's burden of
chronic lung disease is exacerbated by late diagnoses and inadequate
screening. Our newly granted patent for gas exchange imaging will help expand
the use of Xenon MRI in China to visualise lung function and vascular health -
potentially enabling earlier detection, better monitoring of disease
progression, and providing a new tool to help clinicians improve the long-term
outlook for conditions like COPD, asthma, and ILD."

 

Enquiries:

 

 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer        Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                             +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                     (mailto:polarean@walbrookpr.com)
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

 

About Polarean

 

Polarean is a revenue-generating medical imaging technology company
revolutionizing pulmonary medicine through direct visualization of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimize lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarised xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGZMKLRGKZM